Rabies vaccines

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 646-668

  Rupprecht, Charles E ^a   Plotkin, Stanley A ^b,c  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902064974     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00036-7     Document Type: Chapter

References (519)

1. Kuzmin I.V., Mayer A.E., Niezgoda M., et al. Shimoni bat virus, a new representative of the Lyssavirus genus. Virus Res 2010, 149:197-210.
2. Freuling C., Beer M., Contraths F.J., et al. Novel Lyssavirus in Natterer's bat, Germany. Emerg Infect Dis 2011, 17:1519-1522.
3. Shantavasinkul P., Tantawichien T., Jaijaroensup W., et al. A 4-site, single-visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with > 5000 patients. Clin Infect Dis 2010, 51:1070-1072.
4. Dacheux L., Wacharapluesadee S., Hemachudha T., et al. More accurate insight into the incidence of human rabies in developing countries through validated laboratory techniques. PLoS Negl Trop Dis 2010, 4:e765. doi: 10.1371/journal.pntd.0000765.
5. Horton D.L., McElhinney L.M., Marston D.A., et al. Quantifying antigenic relationships among the lyssaviruses. J Virol 2010, 84:11841-11848.
6. + T cell-dependent activation of NK cells following vaccination. J Immunol 2010, 185:2808-2818.
7. Sudarshan M.K., Gangaboraiah B., Ravish H.S., et al. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis. Hum Vaccin 2010, 6:562-565.
8. Hampson K., Cleaveland S., Briggs D. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. PLoS Negl Trop Dis 2011, 5:e982. doi:10.1371/journal.pntd.0000982.
9. Lembo T., Attlan M., Bourhy H., et al. Renewed global partnerships and redesigned roadmaps for rabies prevention and control. Vet Med Int 2011, 2011:923149. doi:10.4061/2011/923149.
10. Warrell M.J. Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Curr Top Microbiol Immunol 2012, 351:139-157.
11. Briggs D.J. Rabies: the immunological basis for immunization series: module 17 2011, World Health Organization, Geneva, Switzerland.
12. Wiktor T. Historical aspects of rabies treatment. World's Debt to Pasteur 1985, 141-151. Alan R. Liss, New York, NY. H. Koprowski, S.A. Plotkin (Eds.).
13. Theodorides J. Histoire de la Rage 1986, 1-289. Masson, Paris, France.
14. Pasteur L. Method pour prevenir la rage apres morsure. C R Acad Sci 1885, 101:765-772.
15. Benitez R.M. A 39-year-old man with mental status change. Md Med J 1996, 45:765-769.
16. Hemachudha T., Laothamatas J., Rupprecht C.E. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002, 1:101-109.
17. Hattwick M.A. Human rabies. Public Health Rev 1974, 3:229-274.
18. Smith J.S., Fishbein D.B., Rupprecht C.E., et al. Unexplained rabies in three immigrants in the United States: a virologic investigation. N Engl J Med 1991, 324:205-211.
19. Warrell D.A. Rabies on the doorstep. Adv Exp Med Biol 2005, 568:145-160.
20. Hemachudha T. Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr Top Microbiol Immunol 1994, 187:121-143.
21. Warrell D.A. The clinical picture of rabies in man. Trans R Soc Trop Med Hyg 1976, 70:188-195.
22. Anderson L.J., Nicholson K.G., Tauxe R.V., et al. Human rabies in the United States, 1960 to 1979: epidemiology, diagnosis, and prevention. Ann Intern Med 1984, 100:728-735.
23. Awasthi M., Parmar H., Patankar T., et al. Imaging findings in rabies encephalitis. AJNR Am J Neuroradiol 2001, 22:677-680.
24. Dodet B., Meslin F.X., Heseltine E. Clinical aspects of human rabies. In: Fourth International Symposium on rabies control in Asia March 5-9, 2001, World Health Organization, Paris, France.
25. Baevsky R.H., Bartfield J.M. Human rabies: a review. Am J Emerg Med 1993, 11:279-286.
26. Mani J., Reddy B.C., Borgohain R., et al. Magnetic resonance imaging in rabies. Postgrad Med J 2003, 79:352-354.
27. Laothamatas J., Hemachudha T., Mitrabhakdi E., et al. MR imaging in human rabies. AJNR Am J Neuroradiol 2003, 24:1102-1109.
28. Maschke M., Kastrup O., Forsting M., et al. Update on neuroimaging in infectious central nervous system disease. Curr Opin Neurol 2004, 17:475-480.
29. Hattwick M.A., Weis T.T., Stechschulte C.J., et al. Recovery from rabies: a case report. Ann Intern Med 1972, 76:931-942.
30. Porras C., Barboza J.J., Fuenzalida E., et al. Recovery from rabies in man. Ann Intern Med 1976, 85:44-48.
31. Winkler W.G., Fashinell T.R., Leffingwell L., et al. Airborne rabies transmission in a laboratory worker. JAMA 1973, 226:1219-1221.
32. Gode G.R., Saksena R., Batra R.K., et al. Treatment of 54 clinically diagnosed rabies patients with two survivals. Indian J Med Res 1988, 88:564-566.
33. Alvarez L., Fajardo R., Lopez E., et al. Partial recovery from rabies in a nine-year-old boy. Pediatr Infect Dis J 1994, 13:1154-1155.
34. Madhusudana S.N., Nagaraj D., Uday M., et al. Partial recovery from rabies in a six-year-old girl. Int J Infect Dis 2002, 6:85-86.
35. Dutta J.K. Adverse reactions to purified chick embryo cell rabies vaccine. Vaccine 1994, 12:1484.
36. Willoughby R.E., Tieves K.S., Hoffman G.M., et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005, 352:2508-2514.
37. Jackson A.C. Rabies virus infection: an update. J Neurovirol 2003, 9:253-258.
38. Jackson A.C. Recovery from rabies. N Engl J Med 2005, 352:2549-2550.
39. CDC. Recovery of a patient from clinical rabies - California. MMWR Morb Mortal Wkly Rep. 2012, 61:61-65.
40. Hemachudha T., Sunsaneewitayaku B., Desudchit T., et al. Failure of therapeutic coma and ketamine for therapy of human rabies. J Neurovirol 2006, 12:407-409.
41. Rupprecht C.E., Willoughby R., Slate D. Current and future trends in the prevention, treatment and control of rabies. Expert Rev Anti Infect Ther 2006, 4:1021-1038.
42. Fekadu M. Atypical rabies in dogs in Ethiopia. Ethiop Med J 1972, 10:79-86.
43. Albertini A.A., Wernimont A.K., Muziol T., et al. Crystal structure of the rabies virus nucleoprotein-RNA complex. Science 2006, 313:360-363.
44. Wunner W.H., Dietzschold B., Wiktor T. Antigenic structure of rhabdoviruses. Immunochemistry of Viruses: The Basis for Serodiagnosis and Vaccines 1985, 367-388. Elsevier Science, New York, NY. M.H.V. VonRegenmortel, A.D. Neurath (Eds.).
45. Kissi B., Badrane H., Audry L., et al. Dynamics of rabies virus quasispecies during serial passages in heterologous hosts. J Gen Virol 1999, 80(pt 8):2041-2050.
46. Morimoto K., McGettigan J.P., Foley H.D., et al. Genetic engineering of live rabies vaccines. Vaccine 2001, 19:3543-3551.
47. Badrane H., Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 2001, 75:8096-8104.
48. Holmes E.C., Woelk C.H., Kassis R., et al. Genetic constraints and the adaptive evolution of rabies virus in nature. Virology 2002, 292:247-257.
49. Davis P.L., Bourhy H., Holms E.C. The evolutionary history and dynamics of bat rabies virus. Infect Genet Evol 2006, 6:464-473.
50. Hughes G.J., Orciari L.A., Rupprecht C.E. Evolutionary timescale of rabies virus adaptation to North American bats inferred from the substitution rate of the nucleoprotein gene. J Gen Virol 2005, 86(pt 5):1467-1474.
51. Wiktor T.J., Gyorgy E., Schlumberger D., et al. Antigenic properties of rabies virus components. J Immunol 1973, 110:269-276.
52. Gaudin Y., Ruigrok R.W., Tuffereau C., et al. Rabies virus glycoprotein is a trimer. Virology 1992, 187:627-632.
53. Ito N., Takayama M., Yamada K., et al. Rescue of rabies virus from cloned cDNA and identification of the pathogenicity-related gene: glycoprotein gene is associated with virulence for adult mice. J Virol 2001, 75:9121-9128.
54. Dietzschold B., Wunner W.H., Wiktor T., et al. Characterization of an antigenic determinant of the glycoprotein which defines pathogenicity of fixed rabies virus strains. Proc Natl Acad Sci U S A 1982, 80:70-74.
55. Anilionis A., Wunner W.H., Curtis P.J. Structure of the glycoprotein gene in rabies virus. Nature 1981, 294:275-278.
56. Faber M., Faber M.L., Papaneri A., et al. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol 2005, 79:14141-14148.
57. Wunner W.H., Dietzschold B. Rabies virus infection: genetic mutations and the impact on viral pathogenicity and immunity. Contrib Microbiol Immunol 1987, 8:103-124.
58. Yamada K., Ito N., Takayama Ito M., et al. Multigenic relation to the attenuation of rabies virus. Microbiol Immunol 2006, 50:25-32.
59. Brzozka K., Finke S., Conzelmann K.K. Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor. J Virol 2005, 79:7673-7681.
60. Vidy A., Chelbi Alix M., Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol 2005, 79:14411-14420.
61. Schnell M.J., Tan G.S., Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J Neurovirol 2005, 11:76-81.
62. Prehaud C., Lay S., Dietzschold B., et al. Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis. J Virol 2003, 77:10537-10547.
63. Lafon M. Subversive neuroinvasive strategy of rabies virus. Arch Virol Suppl 2004, 18:149-159.
64. Finke S., Conzelmann K.K. Replication strategies of rabies virus. Virus Res 2005, 111:120-131.
65. Albertini A.A., Wernimont A.K., Muziol T., et al. Crystal structure of the rabies virus nucleoprotein-RNA complex. Science 2006, 313:360-364.
66. Dietzschold B., Ertl H.C. New developments in the pre- and post-exposure treatment of rabies 22. Crit Rev Immunol 1991, 10:427-439.
67. Nathanson N., Gonzalez-Scarano F. New developments in the pre- and post-exposure treatment of rabies. The Natural History of Rabies 1991, 145-161. CRC Press, Boca Raton, FL. G.M. Baer (Ed.).
68. Xiang Z.Q., Knowles B.B., McCarrick J.W. Immune effector mechanisms required for protection to rabies virus. Virology 1995, 214:398-404.
69. Hemachudha T., Wacharapluesadee S., Lumlertdaecha B., et al. Sequence analysis of rabies virus in humans exhibiting encephalitic or paralytic rabies. J Infect Dis 2003, 188:960-966.
70. Smith J.S. New aspects of rabies with emphasis on epidemiology, diagnosis, and prevention of the disease in the United States. Clin Microbiol Rev 1996, 9:166-176.
71. Crick J., Tignor G.H., Moreno K. A new isolate of Lagos bat virus from the Republic of South Africa. Trans R Soc Trop Med Hyg 1982, 76:211-213.
72. Schneider L.G., Barnard B.J., Schneider H. Application of monoclonal antibodies for epidemiological investigations and oral vaccine studies, I: African viruses 1983.
73. Lumio J., Hillbom M., Roine R., et al. Human rabies of bat origin in Europe. Lancet 1986, 1:378.
74. Foggin C.M. Rabies in Africa with emphasis on rabies-related viruses. World's Debt to Pasteur 1985, 219-234. Alan R Liss, New York, NY. H. Koprowski, S.A. Plotkin (Eds.).
75. Shope R.E. Rabies virus antigenic relationships. The Natural History of Rabies 1975, 141-152. Academic Press, New York, NY. G.M. Baer (Ed.).
76. Gardner S.D. Bat rabies in Europe. J Infect 1989, 18:205-208.
77. Fooks A.R., Brookes S.M., Johnson N., et al. European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 2003, 131:1029-1039.
78. Lafon M., Herzog M., Sureau P. Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage). Lancet 1986, 2:515.
79. Herzog M., Fritzell C., Lafage M., et al. T and B cell human responses to European bat Lyssavirus after post-exposure rabies vaccination. Clin Exp Immunol 1991, 85:224-230.
80. Nel L.H. Vaccines for lyssaviruses other than rabies. Expert Rev Vaccines 2005, 4:533-540.
81. Kuzmin I.V., Hughes G.J., Botvinkin A.D., et al. Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for Lyssavirus genotype definition. Virus Res 2005, 111:28-43.
82. Kuzmin I.V., Mayer A.E., Niezgoda M., et al. Shimoni bat virus, a new representative of the Lyssavirus genus. Virus Res 2010, 149:197-210.
83. Kuzmin I.V., Turmelle A.S., Agwanda B., et al. Commerson's leaf-nosed bat (Hipposideros commersoni) is the likely reservoir of Shimoni bat virus. Vector Borne Zoonotic Dis 2011, 11:1465-1470.
84. Freuling C., Beer M., Contraths F.J., et al. Novel Lyssavirus in Natterer's bat, Germany. Emerg Infect Dis 2011, 17:1519-1522.
85. Shankar V., Dietzschold B., Koprowski H. Direct entry of rabies virus into the central nervous system without prior local replication. J Virol 1991, 65:2736-2738.
86. Ray N.B., Ewalt L.C., Lodmell D.L. Rabies virus replication in primary murine bone marrow macrophages and in human and murine macrophage-like cell lines: implications for viral persistence. J Virol 1995, 69:764-772.
87. Charlton K.M. The pathogenesis of rabies and other lyssaviral infections: recent studies. Curr Top Microbiol Immunol 1994, 187:95-119.
88. Lafon M. Rabies virus receptors. J Neurovirol 2005, 11:82-87.
89. Lentz T.L., Wilson P.T., Hawrot E., et al. Amino acid sequence similarity between rabies virus glycoprotein and snake venom curaremimetic neurotoxins. Science 1984, 226:847-848.
90. Bracci L., Antoni G., Cusi M.G., et al. Antipeptide monoclonal antibodies inhibit the binding of rabies virus glycoprotein and alpha-bungarotoxin to the nicotinic acetylcholine receptor. Mol Immunol 1988, 25:881-888.
91. Gastka M., Horvath J., Lentz T.L. Rabies virus binding to the nicotinic acetylcholine receptor alpha subunit demonstrated by virus overlay protein binding assay. J Gen Virol 1996, 77(pt 10):2437-2440.
92. Tsiang H. Pathophysiology of rabies virus infection of the nervous system. Adv Virus Res 1993, 42:375-412.
93. Tsiang H., Derer M., Taxi J. An in and in study of rabies virus infection of the rat superior cervical ganglia. Arch Virol 1983, 76:231-243.
94. Clark H.F., Prabhakar B.S. Rabies. Comparative Pathobiology of Viral Diseases 1985, 165-214. CRC Press, Boca Raton, FL. R.G. Oslen, S. Krakowa (Eds.).
95. Spriggs D.R. Rabies pathogenesis: fast times at the neuromuscular junction. J Infect Dis 1985, 152:1362-1363.
96. Dietzschold B., Kao M., Zheng Y.M., et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A 1992, 89:7252-7256. [published correction appears in Proc Natl Acad Sci U S A 1992;89:9365].
97. Dietzschold B., Morimoto K., Hooper D.C. Mechanisms of virus-induced neuronal damage and the clearance of viruses from CNS. The mechanisms of neuronal damage in virus infections of the nervous system 2001, 145-155. Springer, New York, NY. G. Gosztonyi (Ed.).
98. Tsiang H. Pathophysiology of rabies virus infection of the nervous system. Adv Virus Res 1993, 42:375-412.
99. Jackson A.C., Ye H., Phelan C.C., et al. Extraneural organ involvement in human rabies. Lab Invest 1999, 79:945-951.
100. Jogai S., Radotra B.D., Banerjee A.K. Rabies viral antigen in extracranial organs: a post-mortem study. Neuropathol Appl Neurobiol 2002, 28:334-338.
101. Fu Z.F., Jackson A.C. Neuronal dysfunction and death in rabies virus infection. J Neurovirol 2005, 11:101-106.
102. Jackson A.C., Park H. Apoptotic cell death in experimental rabies in suckling mice. Acta Neuropathol (Berl) 1998, 95:159-164.
103. Jackson A.C., Ye H., Ridaura-Sanz C., et al. Quantitative study of the infection in brain neurons in human rabies. J Med Virol 2001, 65:614-618.
104. Juntrakul S., Ruangvejvorachai P., Shuangshoti S., et al. Mechanisms of escape phenomenon of spinal cord and brainstem in human rabies. BMC Infect Dis 2005, 5:104. doi:10.1186/1471-2334-5-104.
105. Wang Z.W., Sarmento L., Wang Y., et al. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 2005, 79:12554-12565.
106. Li X.Q., Sarmento L., Fu Z.F. Degeneration of neuronal processes after infection with pathogenic, but not attenuated, rabies viruses. J Virol 2005, 79:10063-10068.
107. Fekadu M. Latency and aborted rabies. The Natural History of Rabies 1991, 191-198. CRC Press, Boca Raton, FL. G.M. Baer (Ed.).
108. Mitrabhakdi E., Shuangshoti S., Wannakrairot P., et al. Difference in neuropathogenetic mechanisms in human furious and paralytic rabies. J Neurol Sci 2005, 238:3-10.
109. Hemachudha T., Wacharapluesadee S., Laotamatas H., et al. Rabies. Curr Neurol Neurosci Rep 2006, 6:460-468.
110. Hemachudha T., Wacharapluesadee S., Mitrabhakdi E., et al. Pathophysiology of human paralytic rabies. J Neurovirol 2005, 11:93-100.
111. Hooper D.C. The role of immune responses in the pathogenesis of rabies. J Neurovirol 2005, 11:88-92.
112. Hooper D.C., Morimoto K., Bette M., et al. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 1998, 72:3711-3719.
113. Kamolvarin N., Tirawatnpong T., Rattanasiwamoke R., et al. Diagnosis of rabies by polymerase chain reaction with nested primers. J Infect Dis 1993, 167:207-210.
114. Bingham J., van der Merwe M. Distribution of rabies antigen in infected brain material: determining the reliability of different regions of the brain for the rabies fluorescent antibody test. J Virol Methods 2002, 101:85-94.
115. King A.A., Turner G.S. Rabies: a review. J Comp Pathol 1993, 108:1-39.
116. Matsumoto S. Electron microscopy of central nervous system infection. The Natural History of Rabies 1975, 33-61. Academic Press, New York, NY. G.M. Baer (Ed.).
117. Noah D.L., Drenzek C.L., Smith J.S., et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998, 128:922-930.
118. Plotkin S.A. Rabies. Clin Infect Dis 2000, 30:4-12.
119. Wacharapluesadee S., Hemachudha T. Nucleic-acid sequence based amplification in the rapid diagnosis of rabies. Lancet 2001, 358:892-893.
120. Wacharapluesadee S., Hemachudha T. Urine samples for rabies RNA detection in the diagnosis of rabies in humans. Clin Infect Dis 2002, 34:874-875.
121. Hemachudha T., Wacharapluesadee S. Antemortem diagnosis of human rabies. Clin Infect Dis 2004, 39:1085-1086.
122. Kasempimolporn S., Saengseesom W., Lumlertdacha B., et al. Detection of rabies virus antigen in dog saliva using a latex agglutination test. J Clin Microbiol 2000, 38:3098-3099.
123. Muhamuda K., Madhusudana S.N., Ravi V., et al. Presence of rabies specific immune complexes in cerebro-spinal fluid can help in ante-mortem diagnosis of human paralytic rabies. J Clin Virol 2006, 37:162-167.
124. Sang E., Farr R.W., Fisher M.A., et al. Antemortem diagnosis of human rabies. J Fam Pract 1996, 43:83-87.
125. Centers for Disease Control Annual summary 1983: reported morbidity and mortality in the United States. MMWR Morb Mortal Wkly Rep 1984, 32(46).
126. Sabchareon A., Lang J., Attanath P., et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis 1999, 29:141-149.
127. Finnegan C.J., Brookes S.M., Johnson N., et al. Rabies in North America and Europe. J R Soc Med 2002, 95:9-13.
128. Krebs J.W., Strine T.W., Smith J.S., et al. Rabies surveillance in the United States during 1995. J Am Vet Med Assoc 1996, 209:2031-2044.
129. Blanton J., Krebs J.W. Rabies surveillance in the United States during 2005. J Am Vet Med Assoc 2006, 299:1897-1911.
130. From the Centers for Disease Control and Prevention: update: raccoon rabies epizootic-United States, 1996. JAMA 1997, 277:282-283.
131. Chang H.G., Eidson M., Noonan-Toly C., et al. Public health impact of reemergence of rabies, New York. Emerg Infect Dis 2002, 8:909-913.
132. Steck F., Wandeler A. The epidemiology of fox rabies in Europe. Epidemiol Rev 1980, 2:71-96.
133. Potzsch C., Kliemt A., Kloss D., et al. Rabies in Europe: trends and developments. Dev Biol (Basel) 2006, 125:59-68.
134. Bourhy H., Kissi B., Audry L., et al. Ecology and evolution of rabies virus in Europe. J Gen Virol 1999, 80(pt 10):2545-2557.
135. Belotto A., Leanes L.F., Schneider M.C., et al. Overview of rabies in the Americas. Virus Res 2005, 111:5-12.
136. Takayama N. Rabies control in Japan. Jpn J Infect Dis 2000, 53:93-97.
137. Coleman P.G., Dye C. Immunization coverage required to prevent outbreaks of dog rabies. Vaccine 1996, 14:185-186.
138. Tepsumethanon V., Lumlertdacha B., Mitmoonpitak C., et al. Survival of naturally infected rabid dogs and cats. Clin Infect Dis 2004, 39:278-280.
139. Delpietro H.A., Larghi O.P., Russo R.G. Virus isolation from saliva and salivary glands of cattle naturally infected with paralytic rabies. Prev Vet Med 2001, 48:223-228.
140. Mitmoonpitak C., Tepsumethanon V., Wilde H. Rabies in Thailand. Epidemiol Infect 1998, 120:165-169.
141. Wilde H., Chutivongse S., Tepsumethanon W., et al. Rabies in Thailand: 1990. Rev Infect Dis 1991, 13:644-652.
142. Bourhy H., Dacheux L., Strady C., et al. Rabies in Europe in 2005. Euro Surveill 2005, 10:213-216.
143. Pandey P., Shlim D.R., Cave W., et al. Risk of possible exposure to rabies among tourists and foreign residents in Nepal. J Travel Med 2002, 9:127-131.
144. Dietzschold B., Rupprecht C.E., Tollis M., et al. Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implications for epidemiology and control of rabies. Rev Infect Dis 1988, 10(Suppl. 4):S785-S798.
145. Sacramento D., Badrane H., Bourhy H., et al. Molecular epidemiology of rabies virus in France: comparison with vaccine strains. J Gen Virol 1992, 73(pt 5):1149-1158.
146. von Teichman B.F., Thomson G.R., Meredith C.D., et al. Molecular epidemiology of rabies virus in South Africa: evidence for two distinct virus groups. J Gen Virol 1995, 76(pt 1):73-82.
147. Smith J.S., Orciari L.A., Yager P.A., et al. Epidemiologic and historical relationships among 87 rabies virus isolates as determined by limited sequence analysis. J Infect Dis 1992, 166:296-307.
148. Messenger S.L., Smith J.S., Orciari L.A., et al. Emerging pattern of rabies deaths and increased viral infectivity. Emerg Infect Dis 2003, 9:151-154.
149. Pape W.J., Fitzsimmons T.D., Hoffman R.E. Risk for rabies transmission from encounters with bats, Colorado, 1977-1996. Emerg Infect Dis 1999, 5:433-437.
150. Setien A.A., Brochier B., Tordo N., et al. Experimental rabies infection and oral vaccination in vampire bats (Desmodus rotundus. Vaccine 1998, 16:1122-1126.
151. Ronsholt L., Sorensen K.J., Bruschke C.J., et al. Clinically silent rabies infection in (zoo) bats. Vet Rec 1998, 142:519-520.
152. Morimoto K., Patel M., Corisdeo S., et al. Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America. Proc Natl Acad Sci U S A 1996, 93:5653-5658.
153. Dietzschold B., Schnell M., Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol 2005, 292:45-56.
154. Roy A., Phares T.W., Koprowski H., et al. Failure to open the blood-brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection. J Virol 2007, 81:1110-1118.
155. Leslie M.J., Messenger S., Rohde R.E., et al. Bat-associated human rabies virus in skunks. Emerg Infect Dis 2006, 12:1274-1277.
156. da Rosa E.S., Kotait I., Barbosa T.F., et al. Bat-transmitted human rabies outbreaks, Brazilian Amazon. Emerg Infect Dis 2006, 12:1197-1202.
157. Dietzschold B., Hooper D.C. Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV). Vaccine 1998, 16:1656-1659.
158. Gibbons R.V. Cryptogenic rabies, bats, and the question of aerosol transmission. Ann Emerg Med 2002, 39:528-536.
159. Srinivasan A., Burton E.C., Kuehnert M.J., et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005, 352:1103-1111.
160. Rabies prevention: United States, 1991. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40(RR-3):1-19.
161. Johnson N., Phillpotts R., Fooks A.R. Airborne transmission of lyssaviruses. J Med Microbiol 2006, 55(pt 6):785-790.
162. World Health Organization Sixth report of the Expert Committee on Rabies 1973, World Health Organization, Geneva, Switzerland, WHO Technical Report 523.
163. Remington P.L., Shope T., Andrews J. A recommended approach to the evaluation of human rabies exposure in an acute-care hospital. JAMA 1985, 254:67-69.
164. Fekadu M., Endeshaw T., Alemu W., et al. Possible human-to-human transmission of rabies in Ethiopia. Ethiop Med J 1996, 34:123-127.
165. Brogan T.V., Bratton S.L., Dowd M.D., et al. Severe dog bites in children. Pediatrics 1995, 96(5 pt 1):947-950.
166. Wilde H. Managing facial dog bites. J Oral Maxillofac Surg 1995, 53:1368.
167. World Health Organization WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies 2002, WHO/EMC/ZOO/96.6, 1-24, WHO, Geneva, Switzerland.
168. Sudarshan M.K., Madhusudana S.N., Mahendra B.J., et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 2007, 11:29-35.
169. Bernard K.W., Roberts M.A., Sumner J., et al. Human diploid cell rabies vaccine: effectiveness of immunization with small intradermal or subcutaneous doses. JAMA 1982, 247:1138-1142.
170. From the Centers for Disease Control and Prevention: human rabies: California, Georgia, Minnesota, New York and Wisconsin, 2000. JAMA 2001, 285:158-160.
171. Human rabies: California, 1995. MMWR Morb Mortal Wkly Rep 1996, 45:353-356.
172. Krebs J.W., Smith J.S., Rupprecht C.E., et al. Rabies surveillance in the United States during 1997. J Am Vet Med Assoc 1998, 213:1713-1728.
173. Warrell M.J. Human deaths from cryptic bat rabies in the USA. Lancet 1995, 346:65-66.
174. Fermi C. Uber die Immunisierung gegen Wutkrankheit. Z Hyg Infectionskr 1908, 58:233-276.
175. Semple D. The preparation of a safe and efficient antirabic vaccine. Sci Mem Med Sanit Dep India 1911, 44.
176. Parviz S., Chotani R., McCormick J., et al. Rabies deaths in Pakistan: results of ineffective post-exposure treatment. Int J Infect Dis 2004, 8:346-352.
177. Fuenzalida E., Palacios R., Borgono J.M. Anti-rabies antibody response in man to vaccine made from infected suckling-mouse brains. Bull World Health Organ 1964, 30:431-436.
178. Peck F.B., Powell H.M., Culbertson C.G. Duck-embryo rabies vaccine: study of fixed virus vaccine grown in embryonated duck eggs and killed with β-propiolactone. JAMA 1956, 162:1373-1476.
179. Kissling R.E. Growth of rabies virus in non-nervous tissue culture. Proc Soc Exp Biol Med 1958, 98:223-225.
180. Fenje P.A. A rabies vaccine from hamster kidney tissue cultures: preparation and evaluation in animals. Can J Microbiol 1960, 6:605-610.
181. Sudarshan M.K., Mahendra B.J., Madhusudana S.N., et al. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines. Hum Vaccin 2005, 1:187-190.
182. WHO Technical Report 931, 2004 2004, World Health Organization, Geneva, Switzerland.
183. Hayflick L., Moorehead P.S. The serial cultivation of human diploid cell substrates. Exp Cell Res 1961, 25:585-621.
184. Plotkin S.A. Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev Infect Dis 1980, 2:433-448.
185. Wiktor T.J., Plotkin S.A., Grella D.W. Human cell culture rabies vaccine: antibody response in man. JAMA 1973, 224:1170-1171.
186. Wiktor T. Virus vaccines and therapeutic approaches. Rhabdoviruses 3 1980, 1-11. CRC Press, Boca Raton, FL. H.D.L. Bishop (Ed.).
187. Plotkin S.A., Wiktor T. Rabies vaccination. Annu Rev Med 1978, 29:583-591.
188. Bahmanyar M., Fayaz A., Nour-Salehi S., et al. Successful protection of humans exposed to rabies infection: postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976, 236:2751-2754.
189. Winkler W.G. Current status of use of human diploid cell strain rabies vaccine in the United States, May 1984. Improvements in Rabies Post-Exposure Treatment 1985, 3-9. Institute of Public Health. I. Vodopija, K.G. Nicholson, U. Bijok (Eds.).
190. Chippaux A., Chaniot S., Piat A., et al. Stability of freeze-dried tissue culture rabies vaccine. Rabies in the Tropics 1985, 322-324. Springer-Verlag, Berlin, Germany. E.K. Kuwert, C. Merieux, H. Koprowski (Eds.).
191. Nicholson K.G., Burney M.I., Ali S., et al. Stability of human diploid-cell-strain rabies vaccine at high ambient temperatures. Lancet 1983, 1:916-918.
192. Turner G.S., Nicholson K.G., Tyrrell D.A., et al. Evaluation of a human diploid cell strain rabies vaccine: final report of a three year study of pre-exposure immunization. J Hyg (Lond) 1982, 89:101-110.
193. Montagnon B.J. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1989, 70:27-47.
194. Ajjan N., Pilet C. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine 1989, 7:125-128.
195. Suntharasamai P., Warrell M.J., Warrell D.A., et al. New purified Vero-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet 1986, 2:129-131.
196. Wang X.J., Lang J., Tao X.R., et al. Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China. Southeast Asian J Trop Med Public Health 2000, 31:287-294.
197. Lang J., Cetre J.C., Picot N., et al. Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV). Biologicals 1998, 26:299-308.
198. Hafkin B., Hattwick M.A., Smith J.S., et al. A comparison of a WI-38 vaccine and duck embryo vaccine for preexposure rabies prophylaxis. Am J Epidemiol 1978, 107:439-443.
199. Jones R.L., Froeschle J.E., Atmar R.L., et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 2001, 19:4635-4643.
200. Picot N., Le Mener V., Rotivel Y., et al. Booster effect of a new chromatographically purified Vero-cell rabies vaccine (CPRV): immunogenicity and safety of a single or double injection. Trans R Soc Trop Med Hyg 2001, 95:342-344.
201. Quiambao B.P., Lang J., Vital S., et al. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines. Acta Trop 2000, 75:39-52.
202. Frazatti Gallina N.M., Mourao Fuches R.M., Paoli R.L., et al. Vero-cell rabies vaccine produced using serum-free medium. Vaccine 2004, 23:511-517.
203. Bijok U., Vodopija I., Smerdel S., et al. Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials. Behring Inst Mitt November 1984, 155-164.
204. Scheiermann N., Baer J., Hilfenhaus J., et al. Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC)-rabies vaccine in man. Zentralbl Bakteriol Mikrobiol Hyg [A] 1987, 265:439-450.
205. Nicholson K.G., Farrow P.R., Bijok U., et al. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. Vaccine 1987, 5:208-210.
206. Dreesen D.W., Fishbein D.B., Kemp D.T., et al. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989, 7:397-400.
207. Khawplod P., Tantawichien T., Wilde H., et al. Use of rabies vaccines after reconstitution and storage. Clin Infect Dis 2002, 34:404-406.
208. Vodopija I., Baklaic Z., Vodopija R. Rabipur: a reliable vaccine for rabies protection. Vaccine 1999, 17:1739-1741.
209. Sehgal S., Bhattacharya D., Bhardwaj M. Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. J Commun Dis 1995, 27:36-43.
210. Briggs D.J., Dreesen D.W., Nicolay U., et al. Purified chick embryo cell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one- versus two-dose post-exposure booster regimen for previously immunized persons. Vaccine 2000, 19:1055-1060.
211. Arai Y.T., Ogata T., Oya A. Studies on Japanese-produced chick embryo cell culture rabies vaccines. Am J Trop Med Hyg 1991, 44:131-134.
212. Chino F., Oshibuchi S., Ariga H., et al. Skin reaction to yellow fever vaccine after immunization with rabies vaccine of chick embryo cell culture origin. Jpn J Infect Dis 1999, 52:42-44.
213. Lin F.T. The protective effect of the large-scale use of PHKC rabies vaccine in humans in China. Bull World Health Organ 1990, 68:449-454.
214. Lin F.T., Na L. Developments in the production and application of rabies vaccine for human use in China. Trop Doct 2000, 30:14-16.
215. Perrin P., Madhusudana S., Gontier-Jallet C., et al. W. An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Vaccine 1995, 13:1244-1250.
216. Gluck R., Wegmann A., Germanier R., et al. Confirmation of need for rabies immunoglobulin as well as post-exposure vaccine. Lancet 1984, 2:1216-1217.
217. Mahendra B.J., Madhusudana S.N., Sampath G., et al. Immunogenicity, safety and tolerance of a purified duck embryo vaccine (PDEV, VAXIRAB) for rabies post-exposure prophylaxis: results of a multicentric study in India. Hum Vaccin 2010, [published online ahead of print September 30, 2010], doi.org/10.4161/hv.6.9.12216.
218. Berlin B.S., Mitchell J.R., Burgoyne G.H., et al. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine, II: results of clinical studies simulating prophylactic therapy for rabies exposure. JAMA 1983, 249:2663-2665.
219. Burgoyne G.H., Kajiya K.D., Brown D.W., et al. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J Infect Dis 1985, 152:204-210.
220. Berlin B.S. Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination. Am J Public Health 1990, 80:476-477.
221. Warrell M.J. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med Infect Dis 2012, 10:1-15.
222. Morris J., Crowcroft N.S., Fooks A.R., et al. Rabies antibody levels in bat handlers in the United Kingdom: immune response before and after purified chick embryo cell rabies booster vaccination. Hum Vaccin 2007, 3:165-170.
223. Gherardin A., Lau S. Intradermal rabies vaccine [letter]. Med J Aust 2007, 187:58-59.
224. Khawplod P., Jaijaroensup W., Sawangvaree A., et al. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine 2012, 30:2918-2920.
225. Shiota S., Khawplod P., Ahmed K., et al. A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization. Vaccine 2008, 26:6441-6444.
226. Zanetti C.R., Chaves L.B., Silva A.C., et al. Studies on human anti-rabies immunization in Brazil, I: evaluation of the 3 + 1 pre-exposure vaccination schedule under field conditions. Rev Inst Med Trop Sao Paulo 1995, 37:349-352.
227. Fishbein D.B., Sawyer L.A., Reid-Sanden F.L., et al. Administration of human diploid-cell rabies vaccine in the gluteal area. N Engl J Med 1988, 318:124-125.
228. Hasbahceci M., Kiyan M., Eyol E., et al. Human diploid-cell rabies vaccine: efficacy of four doses. Lancet 1996, 347:976-977.
229. Rupprecht C.E., Briggs D., Brown C.M., et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010, 59(RR-2):1-9. [published correction appears in MMWR Recomm Rep 2010;59:493].
230. World Health Organization Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 2007, 82:425-435.
231. Vodopija I., Sureau P., Lafon M., et al. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 1986, 4:245-248.
232. Vodopija I. Current issues in human rabies immunization. Rev Infect Dis 1988, 10(Suppl. 4):S758-S763.
233. Zanetti C.R., Lee L.M., Chaves L.B., et al. Studies on human anti-rabies immunization in Brazil, II: preliminary evaluation of the 2-1-1 schedule for human pre-exposure anti-rabies immunization, employing suckling mouse brain vaccine. Rev Inst Med Trop Sao Paulo 1995, 37:353-356.
234. Chutivongse S., Wilde H., Fishbein D.B., et al. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 1991, 9:573-576.
235. Vodopija I., Sureau P., Smerdel S., et al. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 1988, 6:283-286.
236. Lang J., Simanjuntak G.H., Soerjosembodo S., et al. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Organ 1998, 76:491-495.
237. Vodopija I., Sureau P., Smerdel S., et al. Comparative study of two human diploid rabies vaccines administered with antirabies globulin. Vaccine 1988, 6:489-490.
238. Wasi C., Chaiprasithikul P., Auewarakul P., et al. The abbreviated 2-1-1 schedule of purified chick embryo cell rabies vaccination for rabies postexposure treatment. Southeast Asian J Trop Med Public Health 1993, 24:461-466.
239. Scrimgeour E.M., Mehta F.R. Rabies in Oman: failed postexposure vaccination in a lactating woman bitten by a fox. Int J Infect Dis 2001, 5:160-162.
240. Aoki F.Y., Tyrrell D.A., Hill L.E. Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers. Lancet 1975, 1:660-662.
241. Turner G.S., Aoki F.Y., Nicholson K.G., et al. Human diploid cell strain rabies vaccine: rapid prophylactic immunisation of volunteers with small doses. Lancet 1976, 1:1379-1381.
242. Nicholson K.G., Prestage H., Cole P.J., et al. Multisite intradermal antirabies vaccination: immune responses in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine. Lancet 1981, 2:915-918.
243. World Health Organization Report of a WHO consultation on intradermal application of human rabies vaccines 1995, WHO, Geneva, Switzerland, p. 2-19. Abstract.
244. World Health Organization Intradermal Application of Rabies Vaccines: Report of a WHO Consultation, Bangkok, Thailand 2000, WHO, Geneva, Switzerland.
245. Dreesen D.W., Brown W.J., Kemp D.T., et al. Pre-exposure rabies prophylaxis: efficacy of a new packaging and delivery system for intradermal administration of human diploid cell vaccine. Vaccine 1984, 2:185-188.
246. Khawplod P., Jaijaroensup W., Sawangvaree A., et al. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine 2012, 30:2918-2920.
247. Lau C., Sisson J. The effectiveness of intradermal pre-exposure rabies vaccination in an Australian travel medicine clinic. J Travel Med 2002, 9:285-288.
248. Human rabies, Kenya. MMWR Morb Mortal Wkly Rep 1983, 32:494-495.
249. Warrell M.J., Suntharasamai P., Nicholson K.G., et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. Lancet 1984, 1:874-876.
250. Warrell M.J., Nicholson K.G., Warrell D.A., et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985, 1:1059-1062.
251. Madhusudana S.N., Anand N.P., Shamsundar R. Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies. Natl Med J India 2001, 14:145-147.
252. Khawplod P., Wilde H., Tepsumethanon S., et al. Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin. Clin Infect Dis 2002, 35:1562-1565.
253. Warrell M.J., Riddell A., Yu L.M., et al. A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Negl Trop Dis 2008, 24:e224. doi:10.1371/journal.pntd.0000224.
254. Shantavasinkul P., Tantawichien T., Wilde H., et al. Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clin Infect Dis 2010, 50:56-60.
255. Phanuphak P., Khawplod P., Sirivichayakul S., et al. Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine. Asian Pac J Allergy Immunol 1987, 5:33-37.
256. Khawplod P., Wilde H., Sirikwin S., et al. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006, 24:3084-3086.
257. Chutivongse S., Wilde H., Supich C., et al. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990, 335:896-898.
258. Suntharasamai P. Clinical trials of rabies vaccines in Thailand. Southeast Asian J Trop Med Public Health 1988, 19:537-547.
259. Kamoltham T., Khawplod P., Wilde H. Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. Vaccine 2002, 20:3272-3276.
260. Briggs D.J., Banzhoff A., Nicolay U., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000, 78:693-698.
261. Kositprapa C., Limsuwun K., Wilde H., et al. Immune response to simulated postexposure rabies booster vaccinations in volunteers who received preexposure vaccinations. Clin Infect Dis 1997, 25:614-616.
262. Tantawichien T., Benjavongkulchai M., Limsuwan K., et al. Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. Clin Infect Dis 1999, 28:1100-1103.
263. Madhusudana S.N., Sanjay T.V., Mahendra B.J., et al. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen. Int J Infect Dis 2004, 8:175-179.
264. Ambrozaitis A., Laiskonis A., Balciuniene L., et al. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine 2006, 24:4116-4121.
265. Suntharasamai P., Chaiprasithikul P., Wasi C., et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. Vaccine 1994, 12:508-512.
266. Beran J., Honegr K., Banzhoff A., et al. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Vaccine 2005, 23:3902-3907.
267. Meslin F.X. The challenge to provide affordable rabies post-exposure treatment. Vaccine 2003, 21:4122-4123.
268. Quiambao B.P., Dimaano E.M., Ambas C., et al. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 mL PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005, 23:1709-1714.
269. Miranda M.E., Meslin F.X. Human rabies prevention. Dev Biol (Basel) 2006, 125:155-164.
270. Sudarshan M.K., Madhusudana S.N., Mahendra B.J., et al. Evaluation of a new five-injection, two-site, intradermal schedule for purified chick embryo cell rabies vaccine: a randomized, open-label, active-controlled trial in healthy adult volunteers in India. Curr Therapeutic Res 2005, 66:323-334.
271. Dutta J.K., Warrell M.J., Dutta T.K. Intradermal rabies immunization for pre- and post-exposure prophylaxis. Natl Med J India 1994, 7:119-122.
272. Laurent P.E., Bourhy H., Fantino M., et al. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 2010, 28:5850-5856.
273. Both L., Banyard A.C., van Dolleweerd C., et al. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012, 12:397-407.
274. Babes V., Cerchez T. Traite de la rage. Ann Inst Pasteur (Paris) 1891, 10:625-702.
275. Baltazard M., Ghodssi M. Prevention de la rage humaine. Natl Med J India 1953, 17:366-375.
276. Habel K., Koprowski H. Laboratory data supporting the clinical trial of antirabies serum in persons bitten by a rabid wolf. Bull World Health Organ 1955, 13:773-779.
277. Cho H.C., Lawson K.F. Protection of dogs against death from experimental rabies by postexposure administration of rabies vaccine and hyperimmune globulin (human). Can J Vet Res 1989, 53:434-437.
278. Hanlon C.A., Kuzmin I.V., Blanton J.D., et al. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 2005, 111:44-54.
279. Baer G.M., Cleary W.F. A model in mice for the pathogenesis and treatment of rabies. J Infect Dis 1972, 125:520-527.
280. Devriendt J., Staroukine M., Costy F., et al. Fatal encephalitis apparently due to rabies: occurrence after treatment with human diploid cell vaccine but not rabies immune globulin. JAMA 1982, 248:2304-2306.
281. Wattanasri S., Boonthai P., Thongcharoen P. Human rabies after late administration of human diploid cell vaccine without hyperimmune serum. Lancet 1982, 2:870.
282. Leads from the MMWR: recommendations of the Immunization Practices Advisory Committee (ACIP); rabies prevention-United States, 1984. JAMA 1984, 252:883-884. 887, 891-3.
283. Karliner J.S. Incidence of reactions following administration of antirabies serum. JAMA 1965, 193:359-362.
284. Wilde H., Chomchey P., Punyaratabandhu P., et al. Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull World Health Organ 1989, 67:731-736.
285. Tantawichien T., Benjavongkulchai M., Wilde H., et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis 1995, 21:660-662.
286. Satpathy D.M., Sahu T., Behera T.R. Equine rabies immunoglobulin: a study on its clinical safety. J Indian Med Assoc 2005, 103:238-242.
287. Lang J., Gravenstein S., Briggs D., et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 1998, 26:7-15.
288. Lang J., Attanath P., Quiambao B., et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop 1998, 70:317-333.
289. Wilde H., Khawplod P., Hemachudha T., et al. Postexposure treatment of rabies infection: can it be done without immunoglobulin?. Clin Infect Dis 2002, 34:477-480.
290. Quiambao B.P., Dytioco H.Z., Dizon R.M., et al. Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab′)(2) fragment rabies immunoglobulin (Favirab). PLoS Negl Trop Dis 2008, 2:e243. doi:10.1371/journal.pntd.0000243.
291. Helmick C.G., Johnstone C., Sumner J., et al. A clinical study of Merieux human rabies immune globulin. J Biol Stand 1982, 10:357-367.
292. Anderson J.A., Daly F.T., Kidd J.C. Human rabies after antiserum and vaccine postexposure treatment: case report and review. Ann Intern Med 1966, 64:1297-1302.
293. Loofbourow J.C., Cabasso V.J., Roby R.E., et al. Rabies immune globulin (human): clinical trials and dose determination. JAMA 1971, 217:1825-1831.
294. Khawplod P., Wilde H., Chomchey P., et al. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?. Vaccine 1996, 14:389-391.
295. Wilde H., Khawplot P., Benjavongkulchai M., et al. Method of administration of rabies immune globulin. Vaccine 1994, 12:1150-1151.
296. Wilde H., Sirikawin S., Sabcharoen A., et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996, 22:228-232.
297. Ayele W., Fekadu M., Zewdie B., et al. Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. Ethiop Med J 2001, 39:313-321.
298. Thraenhart O., Marcus I., Kreuzfelder E. Current and future immunoprophylaxis against human rabies: reduction of treatment failures and errors. Curr Top Microbiol Immunol 1994, 187:173-194.
299. Khawplod P., Glueck R., Wilde H., et al. Immunogenicity of purified duck embryo rabies vaccine (Lyssavac-N) with use of the WHO-approved intradermal postexposure regimen. Clin Infect Dis 1995, 20:646-651.
300. Rubin R.H., Hattwick M.A., Jones S., et al. Adverse reactions to duck embryo rabies vaccine: range and incidence. Ann Intern Med 1973, 78:643-649.
301. Ajjan N., Soulebot J.P., Triau R., et al. Intradermal immunization with rabies vaccine: inactivated Wistar strain cultivated in human diploid cells. JAMA 1980, 244:2528-2531.
302. Montagnon B.J. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1989, 70:27-47.
303. Turner G.S. Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine. J Gen Virol 1978, 40:595-604.
304. Cabasso V.J., Dobkin M.B., Roby R.E., et al. Antibody response to a human diploid cell rabies vaccine. Appl Microbiol 1974, 27:553-561.
305. Soulebot J.P. Resultats serologiques d'immunization et de hyper-immunization de l'homme avec un nouveau vaccin antirabique obtenu sur cultures de cellules diploides humaines WI-38 1973, colloque, Paris, La Rage.
306. Banmanyar M. Results of antibody profiles in man vaccinated with the HDCS vaccine with various schedules. Symp Series Immunol Stand 1974, 21:231-239.
307. Shah U., Jaswal G.S., Mansharamani H.J., et al. Trial of human diploid cell rabies vaccine in human volunteers. Br Med J 1976, 1:997.
308. Kuwert E.K., Marcus I., Werner J., et al. Post-exposure use of human diploid cell culture rabies vaccine. Dev Biol Stand 1976, 37:273-286.
309. Kuwert E.K., Marcus I., Werner J., et al. Some experiences with human diploid cell strain-(HDCS) rabies vaccine in pre- and post-exposure vaccinated humans. Dev Biol Stand 1978, 40:79-88.
310. Cox J.H., Klietmann W., Schneider L.G. Human rabies immunoprophylaxis using HDC (MRC-5) vaccine. Dev Biol Stand 1978, 40:105-108.
311. Plotkin S.A., Wiktor T. Vaccination of children with human cell culture rabies vaccine. Pediatrics 1979, 63:219-221.
312. Kuwert E.K., Marcus I., Hoher P.G. Neutralizing and complement-fixing antibody responses in pre- and post-exposure vaccinees to a rabies vaccine produced in human diploid cells. J Biol Stand 1976, 4:249-262.
313. Moore S.M., Ricke T.A., Davis R.D., et al. The influence of homologous vs heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals 2005, 33:269-276.
314. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine 2010, 28:3896-3901.
315. Fescharek R., Franke V., Samuel M.R. Do anaesthetics and surgical stress increase the risk of post-exposure rabies treatment failure?. Vaccine 1994, 12:12-13.
316. Thisyakorn U., Pancharoen C., Ruxrungtham K., et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 2000, 30:218.
317. Mastroeni I., Vescia N., Pompa M.G., et al. Immune response of the elderly to rabies vaccines. Vaccine 1994, 12:518-520.
318. Leder K., Weller P.F., Wilson M.E. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001, 33:1553-1566.
319. Suss J., Sinnecker H. Immune reactions against rabies viruses-infection and vaccination. Exp Pathol 1991, 42:1-9.
320. Celis E., Wiktor T.J., Dietzschold B., et al. Amplification of rabies virus-induced stimulation of human T-cell lines and clones by antigen-specific antibodies. J Virol 1985, 56:426-433.
321. Moore S.M., Wilkerson M.J., Davis R.D., et al. Detection of cellular immunity to rabies antigens in human vaccines. J Clin Immunol 2006, 26:533-545.
322. Bracci L., Ballas S.K., Spreafico A., et al. Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination. Blood 1997, 90:3623-3628.
323. Bracci L., Neri P. Molecular mimicry between the rabies virus and human immunodeficiency virus. Arch Pathol Lab Med 1995, 119:391. 393.
324. Pearlman E.S., Ballas S.K. False-positive human immunodeficiency virus screening test related to rabies vaccination. Arch Pathol Lab Med 1994, 118:805-806.
325. Plotkin S.A., Loupi E., Blondeau C. False-positive human immunodeficiency virus screening test related to rabies vaccination. Arch Pathol Lab Med 1995, 119(8):679.
326. Henderson S., Leibnitz G., Turnbull M., et al. False-positive human immunodeficiency virus seroconversion is not common following rabies vaccination. Clin Diagn Lab Immunol 2002, 9:942-943.
327. Robertson K., Recuenco S., Niezgoda M., et al. Seroconversion following incomplete human rabies postexposure prophylaxis. Vaccine 2010, 28:6523-6526.
328. Saraya A., Wacharapluesadee S., Khawplod P., et al. A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens. Vaccine 2010, 28:4553-4557.
329. Sabchareon A. Persistence of antibodies in children after pre-exposure primary and booster immunizations with purified Vero cell rabies vaccine, chromatographically purified Vero cell rabies vaccine and human diploid cell vaccine. Rabies Control in Asia 2001, 29-41. WHO, Paris, France. B. Dodet, F.X. Meslin, E. Heseltine (Eds.).
330. Veeraraghaven N., Subrahmanyan T.P. The value of 5 percent Semple vaccine prepared in distilled water in human treatment: comparative mortality among the treated and untreated. Indian J Med Res 1958, 46:518-524.
331. Nicholson K.G. Modern vaccines: rabies. Lancet 1990, 335:1201-1205.
332. Anderson L.J., Sikes R.K., Langkop C.W., et al. Postexposure trial of a human diploid cell strain rabies vaccine. J Infect Dis 1980, 142:133-138.
333. Wilde H., Glueck R., Khawplod P., et al. Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients. Vaccine 1995, 13:593-596.
334. Christian K.A., Blanton J.D., Auslander M., et al. Epidemiology of rabies post-exposure prophylaxis: United States of America, 2006-2008. Vaccine 2009, 27:7156-7161.
335. Toovey S. Preventing rabies with the Verorab vaccine: 1985-2005: twenty years of clinical experience. Travel Med Infect Dis 2007, 5:327-348.
336. Sudarshan M.K., Bhardwaj S., Mahendra B.J., et al. An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects. Hum Vaccin 2008, 4:275-279.
337. Rosanoff E., Tint H. Responses to human diploid cell rabies vaccine: neutralizing antibody responses of vaccinees receiving booster doses of human diploid cell rabies vaccine. Am J Epidemiol 1979, 110:322-327.
338. Nicholson K.G., Turner G.S., Aoki F.Y. Immunization with a human diploid cell strain of rabies virus vaccine: two-year results. J Infect Dis 1978, 137:783-788.
339. Morris J., Crowcroft N.S. Pre-Exposure rabies booster vaccinations: a literature review. Dev Biol (Basel) 2006, 125:205-215.
340. Malerczyk C., Briggs D.J., Dreesen D.W., et al. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med 2007, 14:63-64.
341. Thraenhart O., Kreuzfelder E., Hillebrandt M., et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol 1994, 71:287-292.
342. Ranney M., Patridge R., Jay G.D., et al. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers". J Travel Med 2006, 13:329-333.
343. Fishbein D.B., Bernard K.W., Miller K.D., et al. The early kinetics of the neutralizing antibody response after booster immunizations with human diploid cell rabies vaccine. Am J Trop Med Hyg 1986, 35:663-670.
344. Burridge M.J., Sumner J.W., Baer G.M. Intradermal immunization with human diploid cell rabies vaccine: serological and clinical responses of immunized persons to intradermal booster vaccination. Am J Public Health 1984, 74:503-505.
345. Shantavasinkul P., Tantawichien T., Jaijaroensup W., et al. A 4-site, single-visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with > 5000 patients. Clin Infect Dis 2010, 51:1070-1072.
346. Brown D., Featherstone J.J., Fooks A.R., et al. Intradermal pre-exposure rabies vaccine elicits long lasting immunity. Vaccine 2008, 26:3909-3912.
347. Vien N.C., Feroldi E., Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008, 102:294-296.
348. Briggs D.J., Schwenke J.R. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine 1992, 10:125-129.
349. Thisyakorn U., Pancharoen C., Wilde H. Immunologic and virologic evaluation of HIV-1-infected children after rabies vaccination. Vaccine 2001, 19:1534-1537.
350. Sirikwin S., Likanonsakul S., Waradejwinyoo S., et al. Antibody response to an eight-site intradermal rabies vaccination in patients infected with human immunodeficiency virus. Vaccine 2009, 27:4350-4354.
351. Jaijaroensup W., Tantawichien T., Khawplod P., et al. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis 1999, 28:913-914.
352. Pancharoen C., Thisyakorn U., Tantawichien T., et al. Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand J Infect Dis 2001, 33:390-391.
353. Thisyakorn U., Pancharoen C., Ruxrungtham K., et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 2000, 30:218.
354. Deshpande A., Briggs D. Rabies vaccination in immunosuppressed patients 2001, 59-60. Merieux Foundation, WHO, Paris.
355. Rotivel Y., Weber P., Goudal M. Post-exposure treatment of patients with impaired or suboptimal immunity 2001, 5-9. Merieux Foundation, WHO, Paris, 61-5.
356. Deshmukh R.A., Yemul V.L. Fatal rabies encephalitis despite post-exposure vaccination in a diabetic patient: a need for use of rabies immune globulin in all post-exposure cases. J Assoc Physicians India 1999, 47:546-547.
357. Abazeed M.E., Cinti S. Rabies prophylaxis for pregnant women [letter]. Emerg Infect Dis 2007, 13:1966-1967.
358. Sudarshan M.K., Madhusudana S.N., Mahendra B.J. Post-exposure prophylaxis with purified Vero cell rabies vaccine during pregnancy: safety and immunogenicity. J Commun Dis 1999, 31:229-236.
359. Sampath G., Parikh S., Sangram P., et al. Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals. Vaccine 2005, 23:1102-1105.
360. Tanisaro T., Tantawichien T., Tiranathanagul K., et al. Neutralizing antibody response after intradermal rabies vaccination in hemodialysis patients. Vaccine 2010, 28:2385-2387.
361. Cramer C.H., Shieck V., Thomas S.E., et al. Immune response to rabies vaccination in pediatric transplant patients. Pediatr Transplant 2008, 12:874-877.
362. Lodmell D.L., Esposito J.J., Ewalt L.C. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals. Vaccine 2004, 22:3329-3333.
363. Brookes S.M., Parsons G., Johnson N., et al. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 2005, 23:4101-4109.
364. Malerczyk C., Selhorst T., Tordo N., et al. Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat Lyssavirus strains. Vaccine 2009, 27:5320-5325.
365. Moore S.M., Hanlon C.A. Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS Negl Trop Dis 2010, 4:e595. doi:10.1371/journal.pntd.0000595.
366. Baer G.M., Moore S.A., Shaddock J.H., et al. An effective rabies treatment in exposed monkeys: a single dose of interferon inducer and vaccine. Bull World Health Organ 1979, 7:807-813.
367. Madhusudana S.N., Briggs D., Bourhy H. Recent advances in prevention and control of rabies. Adv Prev Med 2011, 2011:956428. doi.org/10.4061/2011/956428.
368. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007, 25:7605-7609.
369. Shantavasinkul P., Tantawichien T., Wacharapluesadee S., et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin Infect Dis 2010, 50:77-79.
370. Hemachudha T., Mitrabhakdi E., Wilde H., et al. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis 1999, 28:143-144.
371. Willoughby R.E. "Early death" and the contraindication of vaccine during treatment of rabies. Vaccine 2009, 27:7173-7177.
372. Fescharek R. What can be learned from a decade of worldwide postmarketing surveillance [abstract]?. International Rabies Meeting 1997, Institut Pasteur, Paris, France, p. 13-4. Abstract 6.07.
373. Gacouin A., Bourhy H., Renaud J.C., et al. Human rabies despite postexposure vaccination. Eur J Clin Microbiol Infect Dis 1999, 18:233-235.
374. Ki-Zerbo G.A., Kyelem N., Ouattara Y., et al. Apropos of a case of rabies occurring despite vaccination after exposure [in French]. Med Trop (Mars) 2000, 60:67-69.
375. Udawat H., Chaudhary H.R., Goyal R.K., et al. Guillain-Barré syndrome following antirabies Semple vaccine: a report of six cases. J Assoc Physicians India 2001, 49:384-385.
376. Gupta V., Bandyopadhyay S., Bapuraj J.R., et al. Bilateral optic neuritis complicating rabies vaccination. Retina 2004, 24:179-181.
377. Javier R.S., Kunishita T., Koike F., et al. Semple rabies vaccine: presence of myelin basic protein and proteolipid protein and its activity in experimental allergic encephalomyelitis. J Neurol Sci 1989, 93:221-230.
378. Laouini D., Kennou M.F., Khoufi S., et al. Antibodies to human myelin proteins and gangliosides in patients with acute neuroparalytic accidents induced by brain-derived rabies vaccine. J Neuroimmunol 1998, 91:63-72.
379. Bahri F., Letaief A., Ernez M., et al. Neurological complications in adults following rabies vaccine prepared from animal brains [in French]. Presse Med 1996, 25:491-493.
380. Habel K. Evaluation of a mouse test for the standardization of the immunizing power of antirabies vaccines. Public Health Rep 1940, 55:1473.
381. Mattner F., Bitz F., Goedecke M., et al. Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients. Infection 2007, 35:219-224.
382. Dobardzic A., Izurieta H., Woo E.J., et al. Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 2007, 25:4244-4251.
383. Ashwathnarayana D.H., Madhusudana S.N., Sampath G., et al. A comparative study on the safety and immunogenicity of purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purified Vero cell rabies vaccine (PVRV, Verorab). Vaccine 2009, 28:148-151. [published correction appears in Vaccine 2010;28:2575].
384. Pengsaa K., Limkittikul K., Sabchareon A., et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr Infect Dis J 2009, 28:335-337.
385. Centers for Disease Control Systemic allergic reactions following immunization with human diploid cell rabies vaccine. MMWR Morb Mortal Wkly Rep 1984, 33:185-188.
386. Dreesen D.W., Bernard K.W., Parker R.A., et al. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 1986, 4:45-49.
387. Fishbein D.B., Yenne K.M., Dreesen D.W., et al. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 1993, 11:1390-1394.
388. Centers for Disease Control ACIP rabies prevention: United States, 1984. MMWR Morb Mortal Wkly Rep 1984, 33:393-407.
389. Anderson M.C., Baer H., Frazier D.J., et al. The role of specific IgE and β-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine. J Allergy Clin Immunol 1987, 80:861-868.
390. Swanson M.C., Rosanoff E., Gurwith M., et al. IgE and IgG antibodies to β-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 1987, 155:909-913.
391. Fishbein D.B., Dreesen D.W., Holmes D.F., et al. Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations. Vaccine 1989, 7:437-442.
392. Briggs D.J., Dreesen D.W., Morgan P., et al. Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults. Vaccine 1996, 14:1361-1365.
393. Bernard K.W., Smith P.W., Kader F.J., et al. Neuroparalytic illness and human diploid cell rabies vaccine. JAMA 1982, 248:3136-3138.
394. Boe E., Nyland H. Guillain-Barré syndrome after vaccination with human diploid cell rabies vaccine. Scand J Infect Dis 1980, 12:231-232.
395. Knittel T., Ramadori G., Mayet W.J., et al. Guillain-Barré syndrome and human diploid cell rabies vaccine. Lancet 1989, 1:1334-1335.
396. Tornatore C.S., Richert J.R. CNS demyelination associated with diploid cell rabies vaccine. Lancet 1990, 335:1346-1347.
397. Moulignier A., Richer A., Fritzell C., et al. Meningoradiculitis after injection of an antirabies vaccine: a vaccine from human diploid cell culture [in French]. Presse Med 1991, 20:1121-1123.
398. Haber P., Sejvar J., Mikaeloff Y., et al. Vaccines and Guillain-Barré syndrome. Drug Saf 2009, 32:309-323.
399. Thongcharoen P., Wasi C., Chavanich L., et al. Rabies in Thailand. Viral Disease in South-East Asia and Western Pacific 1982, 606. Academic Press, New York, NY. J.S. Mackenzie (Ed.).
400. Saxena R., Sethi H.S., Rai H.K., et al. Bilateral neuro-retinitis following chick embryo cell anti-rabies vaccination: a case report. BMC Ophthalmol 2005, 5:20. doi:10.1186/1471-2415-5-20.
401. Arguin P.M., Krebs J.W., Mandel E., et al. Survey of rabies preexposure and postexposure prophylaxis among missionary personnel stationed outside the United States. J Travel Med 2000, 7:10-14.
402. Phanupak P., Ubolyam S., Sirivichayakul S. Should travellers in rabies endemic areas receive pre-exposure rabies immunization?. Ann Med Interne (Paris) 1994, 145:409-411.
403. Wilde H. Preexposure rabies vaccination. J Travel Med 1993, 1:51-54.
404. LeGuerrier P., Pilon P.A., Deshaies D. Pre-exposure rabies prophylaxis for the international traveller: a decision analysis. Vaccine 1996, 14:167-176.
405. Blanton J.D., Rupprecht C.E. Travel vaccination for rabies. Expert Rev Vaccines 2008, 7:613-620.
406. Fridell E., Grandien M., Johansson R. Pre-exposure prophylaxis against rabies in children by human diploid cell vaccine. Lancet 1984, 1:623.
407. Lumbiganon P., Chaiprasithikul P., Sookpranee T., et al. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. Asian Pac J Allergy Immunol 1989, 7:99-101.
408. Bhanganada K., Wilde H., Sakolsataydorn P., et al. Dog-bite injuries at a Bangkok teaching hospital. Acta Trop 1993, 55:249-255.
409. Lang J., Duong G.H., Nguyen V.G., et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet 1997, 349:1663-1665.
410. Lang J., Hoa D.Q., Gioi N.V., et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on Immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999, 93:208-213.
411. Chulasugandha P., Khawplod P., Havanond P., et al. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine 2006, 24:1478-1482.
412. Strady A., Lang J., Lienard M., et al. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998, 177:1290-1295.
413. Strady C., Jaussaud R., Beguinot I., et al. Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine 2000, 18:2661-2667.
414. Strady C., Hung Nguyen V., Jaussaud R., et al. Pre-exposure rabies vaccination: strategies and cost-minimization study. Vaccine 2001, 19:1416-1424.
415. Wilde H. Rabies. Int J Infect Dis 1996, 1:135-142.
416. Fleisher G.R. The management of bite wounds. N Engl J Med 1999, 340:138-140.
417. Plotkin S.A., Clark H.F. Rabies. Textbook of Pediatric Infectious Diseases 1998, 2111-2115. WB Saunders, Philadelphia, PA. R.D. Feigin, J.D. Cherry (Eds.).
418. Mann J.M. Systematic decision-making in rabies prophylaxis. Pediatr Infect Dis 1983, 2:162-167.
419. Human rabies prevention: United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48(RR-1):1-21.
420. Hemachudha T., Chutivongse S., Wilde H., et al. Latent rabies [letter]. N Engl J Med 1991, 324:1890-1891.
421. Siwasontiwat D., Lumlertdacha B., Polsuwan C., et al. Rabies: is provocation of the biting dog relevant for risk assessment?. Trans R Soc Trop Med Hyg 1992, 86:443.
422. Kaplan M.M., Cohen D., Koprowski H. Studies on the local treatment of wounds for the prevention of rabies. Bull World Health Organ 1962, 26:765-775.
423. Ajjan N., Strady A., Roumiantzeff M., et al. Effectiveness and tolerance of rabies post-exposure treatment with human diploid cell rabies vaccine in children. Rabies in the Tropics 1985, 86-90. Springer-Verlag, Berlin, Germany. E. Kuwert, C. Merieux, H. Koprowski (Eds.).
424. Thongcharoen P., Wasi C., Chavanich L. Post-exposure prophylaxis against rabies in children with human diploid cell vaccine. Lancet 1982, 2:436-437.
425. Lang J., Plotkin S.A. Rabies risk and immunoprophylaxis in children. Adv Pediatr Infect Dis 1997, 13:219-255.
426. Dietzschold B., Hooper D.C. Efficacy of human rabies vaccines for a newly emerging rabies virus strain in North America. In: Program and Abstracts of the 8th International Congress on Infectious Diseases May 1998, International Society for Infectious Disease, Boston, MA, Abstract 53.005.
427. Rotz L.D., Hensley J.A., Rupprecht C.E., et al. Large-scale human exposures to rabid or presumed rabid animals in the United States: 22 cases (1990-1996). J Am Vet Med Assoc 1998, 212:1198-1200.
428. Moran G.J., Talan D.A., Mower W., et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emergency ID Net Study Group. JAMA 2000, 284:1001-1007.
429. Thongcharoen P., Wasi C. Possible factors influencing unsuccessful protection of post-exposure prophylaxis for rabies by human diploid cell vaccine. J Med Assoc Thai 1985, 68:386-387.
430. Gherardin A.W., Scrimgeour D.J., Lau S.C., et al. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine. J Travel Med 2001, 8:122-126.
431. Jaijaroensup W., Limusanno S., Khawplod P., et al. Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination. J Travel Med 1999, 6:234-237.
432. Tantawichien T., Tantawichien T., Supit C., et al. Three-year experience with 4-site intradermal booster vaccination with rabies vaccine for postexposure prophylaxis. Clin Infect Dis 2001, 33:2085-2087.
433. Naraporn N., Khawplod P., Limsuwan K., et al. Immune response to rabies booster vaccination in subjects who had postexposure treatment more than 5 years previously. J Travel Med 1999, 6:134-136.
434. Khawplod P., Wilde H., Yenmuang W., et al. Immune response to tissue culture rabies vaccine in subjects who had previous postexposure treatment with Semple or suckling mouse brain vaccine. Vaccine 1996, 14:1549-1552.
435. Chabala S., Williams M., Amenta R., et al. Confirmed rabies exposure during pregnancy: treatment with human rabies immune globulin and human diploid cell vaccine. Am J Med 1991, 91:423-424.
436. Chutivongse S., Wilde H. Postexposure rabies vaccination during pregnancy: experience with 21 patients. Vaccine 1989, 7:546-548.
437. Chutivongse S., Wilde H., Benjavongkulchai M., et al. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis 1995, 20:818-820.
438. Lumbiganon P., Wasi C. Survival after rabies immunization in newborn infant of affected mother. Lancet 1990, 4:319.
439. Umeno S., Doi Y. The study on the anti-rabic inoculation of dogs and the results of its practical application. Kitasato Arch Exp Med 1921, 4:89.
440. Johnson H.N. Proceedings of the 49th Annual Meeting 1945, United States Livestock Sanitary Association, Washington, DC, p. 99-107.
441. Koprowski H. Studies on chick embryo adapted rabies virus. J Immunol 1948, 533-554.
442. Abelseth M.K. An attenuated rabies vaccine for domestic animals produced in tissue cultures. Can Vet J 1964, 5:279-293.
443. Larghi O.P. Perspectives for rabies control and eradication from domestic species in developing countries. Dev Biol (Basel) 2004, 119:205-212.
444. Kamoltham T., Singhsa J., Promsaranee U., et al. Elimination of human rabies in a canine endemic province in Thailand: five-year programme. Bull World Health Organ 2003, 81:375-381.
445. Brochier B., Thomas I., Iokem A., et al. A field trial in Belgium to control fox rabies by oral immunisation. Vet Rec 1988, 123:618-621.
446. Schneider L.G. Rabies virus vaccines. Dev Biol Stand 1995, 84:49-54.
447. Matouch O., Vitasek J., Semerad Z., et al. Rabies-free status of the Czech Republic after 15 years of oral vaccination. Rev Sci Tech 2007, 26:577-584.
448. Lafay F., Benejean J., Tuffereau C., et al. Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine 1994, 12:317-320.
449. Wiktor T., MacFarlane R.I., Dietzschold B., et al. Immunogenic properties of vaccinia recombinants expressing the rabies glycoprotein. Ann Inst Pasteur (Paris) 1985, 136:405-411.
450. Koprowski H. Rabies oral immunization. Curr Top Microbiol Immunol 1989, 146:137-151.
451. Desmettre P., Languet B., Chappuis G., et al. Use of vaccinia rabies recombinant for oral vaccination of wildlife. Vet Microbiol 1990, 23:227-236.
452. Brochier B., Kieny M.P., Costy F., et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991, 354:520-522.
453. Roscoe D.E., Holste W.C., Sorhage F.E., et al. Efficacy of an oral vaccinia-rabies glycoprotein recombinant vaccine in controlling epidemic raccoon rabies in New Jersey. J Wildl Dis 1998, 34:752-763.
454. Pastoret P.P., Brochier B. Epidemiology and control of fox rabies in Europe. Vaccine 1999, 17:1750-1754.
455. Rupprecht C.E., Blass L., Smith K., et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001, 345:582-586.
456. Brochier B., Boulanger D., Costy F., et al. Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. Vaccine 1994, 12:1368-1371.
457. Rupprecht C.E., Hanlon C.A., Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev Biol (Basel) 2004, 119:173-184.
458. Slate D., Rupprecht C.E., Rooney J.A., et al. Status of oral rabies vaccination in wild carnivores in the United States. Virus Res 2005, 111:68-76.
459. Compendium of animal rabies prevention and control, 2005. J Am Vet Med Assoc 2005, 226:1304-1310.
460. Rupprecht C.E., Hanlon C.A., Blanton J., et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res 2005, 111:101-105.
461. Meslin F.X., Fishbein D.B., Matter H.C. Rationale and prospects for rabies elimination in developing countries. Curr Top Microbiol Immunol 1994, 187:1-26.
462. Veeraraghaven N. Scientific report for 1968 of the Pasteur Institute of Southern India 1969, Local publication by Pasteur Institute, Coonoor, India, p. 36.
463. Hattwick M.A., Gregg M.B. The disease in man. The Natural History of Rabies 1975, 281-304. Academic Press, New York, NY. G.M. Baer (Ed.).
464. Fishbein D.B. Rabies. Infect Dis Clin North Am 1991, 5:53-71.
465. Dutta J.K. Disastrous results of indigenous methods of rabies prevention in developing countries. Int J Infect Dis 2002, 6:236-237.
466. Paolazzi C.C., Perez O., De Filippo J. Rabies vaccine: developments employing molecular biology methods. Mol Biotechnol 1999, 11:137-147.
467. McGettigan J.P. Experimental rabies vaccines for humans. Expert Rev Vaccines 2010, 9:1177-1186.
468. Wiktor T.J., MacFarlane R.I., Reagan K.J., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene 1984. Biotechnology 1992, 24:508-512.
469. Cadoz M., Strady A., Meignier B., et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339:1429-1432.
470. Cadoz M., Strady A., Jaussaud R., et al. Tolerance et immunogenicite de deux vaccins antibiques recombinants: ALVAC-RG et NYVAC-RG. International Rabies Meeting 1997, Institute Pasteur, Paris, p. 3-13.
471. Dietzschold B., Faber M., Schnell M.J. New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2003, 2:399-406.
472. Ertl H.C. Novel vaccines to human rabies. PLoS Negl Trop Dis 2009, 3:e515. doi:10.1371/journal.pntd.0000515.
473. Ito N., Sugiyama M., Yamada K., et al. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol Immunol 2005, 49:971-979.
474. Cenna J., Hunter M., Tan G.S., et al. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis 2009, 200:1251-1260.
475. Faber M., Li J., Kean R.B., et al. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci U S A 2009, 106:11300-11305.
476. Bahloul C., Ahmed S.B., B'chir B.I., et al. Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 2003, 22:177-184.
477. Rai N., Kaushik P., Rai A. Development of rabies DNA vaccine using a recombinant plasmid. Acta Virol 2005, 49:207-210.
478. Xiang Z.Q., Spitalnik S., Tran M., et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 1994, 199:132-140.
479. Osorio J.E., Tomlinson C.C., Frank R.S., et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 1999, 17:1109-1116.
480. Perrin P., Jacob Y., Aguilar-Setien A., et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 1999, 18:479-486.
481. Lodmell D.L., Ray N.B., Parnell M.J., et al. DNA immunization protects nonhuman primates against rabies virus. Nat Med 1998, 4:949-952.
482. Lodmell D.L., Ewalt L.C. Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 2001, 19:2468-2473.
483. Lodmell D.L., Ewalt L.C., Parnell M.J., et al. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus. Vaccine 2006, 24:412-416.
484. Lodmell D.L., Parnell M.J., Bailey J.R., et al. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 2001, 20:838-844.
485. Dietzschold B., Wang H.H., Rupprecht C.E., et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci U S A 1987, 84:9165-9169.
486. Fekadu M., Sumner J.W., Shaddock J.H., et al. Sickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N protein. J Virol 1992, 66:2601-2604.
487. Kasempimolporn S., Hemachudha T., Khawplod P., et al. Human immune response to rabies nucleocapsid and glycoprotein antigens. Clin Exp Immunol 1991, 84:195-199.
488. Celis E., Rupprecht C.E. New and improved vaccines against rabies. New Generation Vaccines 1990, 419-438. Marcel Dekker, New York, NY. G.C. Woodrow, M. Levine (Eds.).
489. Drings A., Jallet C., Chambert B., et al. Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine?. Vaccine 1999, 17:1549-1557.
490. Fu Z.F., Dietzschold B., Schumacher C.L., et al. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc Natl Acad Sci U S A 1991, 88:2001-2005.
491. Prehaud C., Takehara K., Flamand A., et al. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology 1989, 173:390-399.
492. Reagan K.J., Wunner W.H., Wiktor T.J., et al. Anti-idiotypic antibodies induce neutralizing antibodies to rabies virus glycoprotein. J Virol 1983, 48:660-666.
493. Haq T.A., Mason H.S., Clements J.D., et al. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995, 268:714-716.
494. Yusibov V., Hooper D.C., Spitsin S.V., et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 2002, 20:3155-3164.
495. Ashraf S., Singh P.K., Yadav D.K., et al. High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol 2005, 119:1-14.
496. Kositprapa C., Wimalratna O., Chomchey P., et al. Problems with rabies postexposure management: a survey of 499 public hospitals in Thailand. J Travel Med 1998, 5:30-32.
497. Servat A., Lutsch C., Delore V., et al. Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model. Vaccine 2003, 22:244-249.
498. Champion J.M., Kean R.B., Rupprecht C.E., et al. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 2000, 235:81-90.
499. Hanlon C.A., DeMattos C.A., DeMattos C.C., et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 2001, 19:3834-3842.
500. Hanlon C.A., Niezgoda M., Morrill P.A., et al. The incurable wound revisited: progress in human rabies prevention?. Vaccine 2001, 19:2273-2279.
501. Sloan S.E., Hanlon C., Weldon W. Identification and characterization of a human monoclonal antibody that potentially neutralizes a broad panel of rabies virus isolates. Vaccine 2006, 25:2800-2810.
502. Müller T., Dietzschold B., Ertl H., et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009, 3:e542. doi:10.1371/journal.pntd.0000542.
503. Bakker A.B., Python C., Kissling C.J., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
504. Nagarajan T., Rupprecht C.E., Dessain S.K., et al. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr Top Microbiol Immunol 2008, 317:67-101.
505. Prosniak M., Faber M., Hanlon C.A., et al. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 2003, 188:53-56.
506. de Kruif J.A., Bakker A.B., Marissen W.E., et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007, 58:359-368.
507. Bakker A.B., Marissen W.E., Kramer R.A., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in escape mutants. J Virol 2005, 79:9062-9068.
508. Goudsmit J., Marissen W.E., Weldon W.C., et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006, 193:796-801.
509. Ko K., Koprowski H. Plant biopharming of monoclonal antibodies. Virus Res 2005, 111:93-100.
510. Girard L.S., Fabis M.J., Bastin M., et al. Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture. Biochem Biophys Res Commun 2006, 345:602-607.
511. Dacheux L., Wacharapluesadee S., Hemachudha T., et al. More accurate insight into the incidence of human rabies in developing countries through validated laboratory techniques. PLoS Negl Trop Dis 2010, 4:e765. doi:10.1371/journal.pntd.0000765.
512. Horton D.L., McElhinney L.M., Marston D.A., et al. Quantifying antigenic relationships among the lyssaviruses. J Virol 2010, 84:11841-11848.
513. + T cell-dependent activation of NK cells following vaccination. J Immunol 2010, 185:2808-2818.
514. Sudarshan M.K., Gangaboraiah B., Ravish H.S., et al. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis. Hum Vaccin 2010, 6:562-565.
515. Hampson K., Cleaveland S., Briggs D. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. PLoS Negl Trop Dis 2011, 5:e982.. doi:10.1371/journal.pntd.0000982.
516. Lembo T., Attlan M., Bourhy H., et al. Renewed global partnerships and redesigned roadmaps for rabies prevention and control. Vet Med Int 2011, 2011:923149. doi:10.4061/2011/923149.
517. Warrell M.J. Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Curr Top Microbiol Immunol 2012, 351:139-157.
518. Modelska A., Dietzschold B., Sleysh N., et al. Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci U S A 1998, 95:2481-2485.
519. Briggs D.J. Rabies: the immunological basis for immunization series: 2011, World Health Organization, Switzerland, module 17.